Does Rallies show Form 4 insider transactions for IMUX?

Yes. Rallies tracks IMUX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is IMUX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IMUX. It does not provide personalized investment advice.

IMUX (Immunic, Inc. Common Stock) Stock Analysis - Insider Trades

Immunic, Inc. Common Stock (IMUX) is a publicly traded Healthcare sector company. As of May 21, 2026, IMUX trades at $11.11 with a market cap of $158.83M and a P/E ratio of -17.70. IMUX moved -0.43% today. Year to date, IMUX is +81.26%; over the trailing twelve months it is +18.63%. Its 52-week range spans $5.06 to $17.30. Analyst consensus is strong buy with an average price target of $38.40. Rallies surfaces IMUX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading IMUX stock inside the company?

Recent IMUX insider activity includes Nash Duane bought 20.00K, Tardio Jason bought 12.51K, Tardio Jason bought 12.51K, Neermann Joerg bought 30.00K, and Vitt Daniel bought 15.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

IMUX Key Metrics

Key financial metrics for IMUX
Metric	Value
Price	$11.11
Market Cap	$158.83M
P/E Ratio	-17.70
EPS	$-0.62
Dividend Yield	0.00%
52-Week High	$17.30
52-Week Low	$5.06
Volume	67
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-97.17M
Gross Margin	0.00%

Recent IMUX Insider Trades

Nash Duane bought 20.00K (~$16.69K) on Jun 13, 2025.
Tardio Jason bought 12.51K (~$9.88K) on Jun 5, 2025.
Tardio Jason bought 12.51K (~$9.88K) on Jun 5, 2025.
Neermann Joerg bought 30.00K (~$22.80K) on Jun 5, 2025.
Vitt Daniel bought 15.00K (~$11.55K) on Jun 4, 2025.

Latest IMUX News

Immunic Raises $200M, Appoints New CMO and Eyes MS Phase 3 Data — May 13, 2026
Immunic Names Veteran Neurologist Michael Panzara as CMO Before Phase 3 ENSURE Readout — Apr 28, 2026
Immunic Executes 1-for-10 Reverse Split, Boosts Share Price to $9.76 — Apr 27, 2026
Immunic Restores Nasdaq Listing by Meeting $1.00 Bid Price for 20 Days — Apr 1, 2026
Immunic secures European patent extending MS drug exclusivity to 2038 — Mar 10, 2026

IMUX Analyst Consensus

7 analysts cover IMUX: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.40.

Common questions about IMUX

Who is trading IMUX stock inside the company?: Recent IMUX insider activity includes Nash Duane bought 20.00K, Tardio Jason bought 12.51K, Tardio Jason bought 12.51K, Neermann Joerg bought 30.00K, and Vitt Daniel bought 15.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IMUX?: Yes. Rallies tracks IMUX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IMUX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IMUX. It does not provide personalized investment advice.